Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
|
Appointment of Chief Executive Officer
On October 26, 2020, we announced the appointment of Richard Adcock as our Chief Executive Officer, and Dr. Patrick
Soon-Shiongs resignation as CEO and his continuation as the Companys executive chair of our board of directors.
Prior to
joining NantKwest, Inc., Mr. Adcock, age 52, served as Chief Executive Officer of Verity Health from January 2018 to September 2020. Verity Health was previously affiliated with Dr. Patrick Soon-Shiong until 2018.
Prior to Verity Health, Mr. Adcock served in various capacities at Sanford Health, including as its Chief Innovation Officer, President, Executive Vice President and Director from 2004 to 2017. Prior to Sanford Health, Mr. Adcock served as
Global Engineering Director at GE Healthcare from 1999 to 2003. Mr. Adcock holds an MBA in Healthcare Management from University of Phoenix and a Bachelors degree in Business Administration.
Compensation Arrangements
We entered
into an offer letter with Mr. Adcock, dated October 20, 2020. The offer letter has no specific term and provides for at-will employment. Mr. Adcocks annual base salary will be $750,000.
Mr. Adcock will be eligible to participate in the annual discretionary bonus plan. The discretionary target bonus will be equal to 50% of his annual base salary (i.e. $375,000 annually) prorated to reflect the partial year of his employment
with the Company during 2020, and he is guaranteed a bonus for calendar year 2021 of at least 50% of his discretionary target bonus (i.e. $187,500). Mr. Adcock must remain employed through the date any bonus is actually paid in order to earn
such bonus.
In addition, in connection with his employment, we have agreed to recommend to our board of directors or an applicable
committee thereof to grant Mr. Adcock an option to purchase 1,000,000 shares of our common stock pursuant to our Amended and Restated 2015 Equity Incentive Plan. The options will have an exercise price equal to the fair market value on the date
of grant (i.e., the closing price as reported on Nasdaq on the date of grant). In addition, the options shall vest according to the following vesting schedule: (i) 25% of the options (i.e., 250,000 options) shall vest on
January 1, 2021; and (ii) the remaining 75% of the options shall vest in equal annual installments over a period of three years from November 1, 2020 (i.e., 25% of the shares subject to the stock option, or 250,000 stock
options, shall vest on each of November 1, 2021, November 1, 2022 and November 1, 2023).
In addition, if
Mr. Adcocks employment is terminated without Cause (as defined in his offer letter), Mr. Adcock will receive a single cash payment equal to twelve (12) months of his then-current annual base salary (i.e., $750,000.), less
all applicable federal, state, and local withholdings and deductions within 2.5 months following the date on which termination occurs, contingent on if he timely signs and does not revoke a release of claims in our favor.
Mr. Adcock will also be eligible to participate in any regular health insurance, retirement, and other benefit plans established by us
from time to time. The Company will also reimburse the costs associated with Mr. Adcocks two current life insurance policies (which equal approximately $30,000.00 annually in the aggregate).
A copy of the press release dated October 26, 2020 announcing Mr. Adcocks appointment as our Chief Executive Officer is
attached hereto as Exhibit 99.1. The summary description of Mr. Adcocks offer letter set forth above does not purport to be complete and is qualified in its entirety by reference to the full text of the offer letter, a copy of which will
be filed as an exhibit to our Form 10-Q for the quarter ended September 30, 2020.
Other Matters
In addition, we are entering into our standard form of indemnification agreement with Mr. Adcock. The form indemnification agreement was
filed with the Securities and Exchange Commission on June 19, 2015 as Exhibit 10.1 to our Registration Statement on Form S-1 (File No. 333-205124) and is
incorporated herein by reference.
Mr. Adcock has no direct or indirect material interest in any transaction required to be disclosed
pursuant to Item 404(a) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended, nor are any such transactions currently proposed. There are no family relationships
between Mr. Adcock and any of our directors or executive officers.